Urban Scheuring

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 616 citations · Full text

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr et al. · Blood · 2005 · 534 citations

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

Bernard Escudier, Cezary Szczylik, Thomas E. Hutson et al. · Journal of Clinical Oncology · 2009 · 489 citations

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Michael Stadler, Martin Bornhäuser, Gesine Bug et al. · Blood · 2005 · 199 citations · Full text

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

David Planchard, Niels Reinmuth, Jürgen R. Fischer et al. · Annals of Oncology · 2020 · 156 citations · Full text